Resveratrol ameliorates renal damage, Increases expression of heme oxygenase-1, And has anti-Complement, Anti-Oxidative, And Anti-Apoptotic effects in a murine model of membranous nephropathy

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Wu, Chia Chao ^a,b   Huang, Yen Sung ^c   Chen, Jin Shuen ^a   Huang, Ching Feng ^a   Su, Sui Lung ^b   Lu, Kuo Cheng ^d   Lin, Yuh Feng ^e   Chu, Pauling ^a   Lin, Shih Hua ^a   Sytwu, Huey Kang ^b  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^d FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; HEME OXYGENASE 1; PROTOPORPHYRIN; RESVERATROL; TRANSCRIPTION FACTOR NRF2; COMPLEMENT; METALLOPORPHYRIN; PROTOPORPHYRIN TIN; REACTIVE OXYGEN METABOLITE; SERUM ALBUMIN; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIAPOPTOTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL ASSAY; COMPLEMENT INHIBITION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; HISTOPATHOLOGY; IMMUNOGLOBULIN PRODUCTION; KIDNEY INJURY; MEMBRANOUS GLOMERULONEPHRITIS; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEINURIA; RENAL PROTECTION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BIOSYNTHESIS; BOVINE; DISEASE MODEL; DRUG EFFECTS; GENETICS; GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULUS; INJURIES; KIDNEY; METABOLISM; PATHOLOGY;

ANIMALS; APOPTOSIS; CATTLE; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; GLOMERULONEPHRITIS, MEMBRANOUS; HEME OXYGENASE-1; KIDNEY; KIDNEY GLOMERULUS; METALLOPORPHYRINS; MICE; OXIDATIVE STRESS; PROTOPORPHYRINS; REACTIVE OXYGEN SPECIES; SERUM ALBUMIN; STILBENES;

EID: 84957550234     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125726     Document Type: Article

References (39)

1. Cattran DC. Idiopathic membranous glomerulonephritis. Kidney Int. 2001; 59(5):1983-1994. PMID: 11318974.
2. Glassock RJ. Diagnosis and natural course of membranous nephropathy. SeminNephrol. 2003; 23 (4):324-332. PMID: 12923720.
3. Ronco P, Debiec H. New insights into the pathogenesis of membranous glomerulonephritis. CurrOpin- NephrolHypertens. 2006; 15(3):258-263.
4. CouserWG, Abrass CK. Pathogenesis of membranous nephropathy. AnnuRevMed. 1988; 39:517-530.
5. Nangaku M, Shankland SJ, Couser WG. Cellular response to injury in membranous nephropathy. JAm- SocNephrol. 2005; 16(5):1195-1204.
6. Cattran D. Management of membranous nephropathy: when and what for treatment. JAmSocNephrol. 2005; 16(5):1188-1194. PMID: 15800117.
7. Glassock RJ. The treatment of idiopathic membranous nephropathy: A dilemma or a conundrum? AmJKidney Dis. 2004; 44(3):562-566. PMID: 15332231
8. du Buf-Vereijken PW, Branten AJ, Wetzels JF. Idiopathic membranous nephropathy: outline and rationale of a treatment strategy. AmJKidney Dis. 2005; 46(6):1012-1029. PMID: 16310567.
9. Bertelli AA, Das DK. Grapes, wines, resveratrol, and heart health. Journal of cardiovascular pharmacology. 2009; 54(6):468-476. doi:10.1097/FJC.0b013e3181bfaff3 PMID: 19770673.
10. Catalgol B, Batirel S, Taga Y, Ozer NK. Resveratrol: French paradox revisited. Frontiers in pharmacology. 2012; 3:141. doi:10.3389/fphar.2012.00141 PMID: 22822401.
11. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet. 1992; 339(8808):1523-1526. PMID: 1351198.
12. He S, Yan X. From resveratrol to its derivatives: new sources of natural antioxidant. Current medicinal chemistry. 2013; 20(8):1005-1017. PMID: 23210785.
13. Kovacic P, Somanathan R. Multifaceted approach to resveratrol bioactivity: Focus on antioxidant action, cell signaling and safety. Oxid Med Cell Longev. 2010; 3(2):86-100. doi:10.4161/oxim.3.2.11147PMID: 20716933.
14. Csiszar A. Anti-inflammatory effects of resveratrol: possible role in prevention of age-related cardiovascular disease. Annals of the New York Academy of Sciences. 2011; 1215:117-122. doi:10.1111/j.1749-6632.2010.05848.x PMID: 21261649.
15. de la Lastra CA, Villegas I. Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Molecular nutrition & food research. 2005; 49(5):405-430.
16. Bhat KP, Lantvit D, Christov K, Mehta RG, Moon RC, Pezzuto JM. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer research. 2001; 61(20):7456-7463. PMID: 11606380.
17. Wu CC, Wu CI, Wang WY, Wu YC. Low concentrations of resveratrol potentiate the antiplatelet effect of prostaglandins. Planta medica. 2007; 73(5):439-443. PMID: 17566146.
18. Signorelli P, Ghidoni R. Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. The Journal of nutritional biochemistry. 2005; 16(8):449-466. PMID: 16043028.
19. Whitlock NC, Baek SJ. The anticancer effects of resveratrol: modulation of transcription factors. Nutrition and cancer. 2012; 64(4):493-502. doi:10.1080/01635581.2012.667862 PMID: 22482424.
20. Wu JM, Hsieh TC. Resveratrol: A cardioprotective substance. Annals of the New York Academy of Sciences. 2011; 1215:16-21. doi:10.1111/j.1749-6632.2010.05854.x PMID: 21261637.
21. Borriello A, Bencivenga D, Caldarelli I, Tramontano A, Borgia A, Zappia V, et al. Resveratrol: from basic studies to bedside. Cancer treatment and research. 2014; 159:167-184. doi:10.1007/978-3-642-38007-5-10 PMID: 24114480.
22. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006; 444(7117):337-342. PMID: 17086191.
23. Chen JS, Chen A, Chang LC, Chang WS, Lee HS, Lin SH, et al. Mouse model of membranous nephropathy induced by cationic bovine serum albumin: Antigen dose-response relations and strain differences. NephrolDialTransplant. 2004; 19(11):2721-2728. PMID: 15385633.
24. Wu CC, Chen JS, Lin SH, Chen A, Sytwu HK, Lin YF. Experimental model of membranous nephropathy in mice: sequence of histological and biochemical events. Lab Anim. 2008; 42(3):350-359. doi:10.1258/la.2007.06016e PMID: 18625590.
25. Wu CC, Chen JS, Chen SJ, Lin SH, Chen A, Chang LC, et al. Kinetics of adaptive immunity to cationic bovine serum albumin-induced membranous nephropathy. Kidney Int. 2007; 72(7):831-840. PMID: 17622271.
26. Wu CC, Lu KC, Chen JS, Hsieh HY, Lin SH, Chu P, et al. HO-1 induction ameliorates experimental murine membranous nephropathy: Anti-oxidative, anti-apoptotic and immunomodulatory effects. Nephrol- DialTransplant. 2008; 23(10):3082-3090. doi:10.1093/ndt/gfn247 PMID: 18477570.
27. Wu CC, Lu KC, Lin YF, Chen JS, Huang CF, Chen CC, et al. Pathogenic role of effector cells and immunoglobulins in cationic bovine serum albumin-induced membranous nephropathy. JClinImmunol. 2012; 32(1):138-149.
28. Huang YS, Hsieh HY, Shih HM, Sytwu HK, Wu CC. Urinary Xist is a potential biomarker for membranous nephropathy. Biochemical and biophysical research communications. 2014; 452(3):415-421. doi:10.1016/j.bbrc.2014.08.077 PMID: 25157805.
29. Son Y, Lee JH, Chung HT, Pae HO. Therapeutic roles of heme oxygenase-1 in metabolic diseases: curcumin and resveratrol analogues as possible inducers of heme oxygenase-1. Oxid Med Cell Longev. 2013; 2013:639541. doi:10.1155/2013/639541PMID: 24101950.
30. Palsamy P, Subramanian S. Resveratrol protects diabetic kidney by attenuating hyperglycemiamediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling. Biochimica et biophysica acta. 2011; 1812(7):719-731. doi:10.1016/j.bbadis.2011.03.008 PMID: 21439372.
31. Cybulsky AV, Quigg RJ, Salant DJ. Experimental membranous nephropathy redux. AmJPhysiol Renal Physiol. 2005; 289(4):F660-F671. PMID: 16159900.
32. Issuree PD, Pushparaj PN, Pervaiz S, Melendez AJ. Resveratrol attenuates C5a-induced inflammatory responses in vitro and in vivo by inhibiting phospholipase D and sphingosine kinase activities. Faseb J. 2009; 23(8):2412-2424. doi:10.1096/fj.09-130542PMID: 19346296.
33. Oh SR, Ryu SY, Park SH, Jung KY, Lee IS, An KS, et al. Anticomplementary activity of stilbenes from medicinal plants. Archives of pharmacal research. 1998; 21(6):703-706. PMID: 9868541.
34. Wood LG, Wark PA, Garg ML. Antioxidant and anti-inflammatory effects of resveratrol in airway disease. Antioxidants & redox signaling. 2010; 13(10):1535-1548.
35. Kitada M, Koya D. Renal protective effects of resveratrol. Oxidative medicine and cellular longevity. 2013; 2013:568093. doi:10.1155/2013/568093 PMID: 24379901.
36. Nihei T, Miura Y, Yagasaki K. Inhibitory effect of resveratrol on proteinuria, hypoalbuminemia and hyperlipidemia in nephritic rats. Life sciences. 2001; 68(25):2845-2852. PMID: 11432450.
37. Bertelli A, Bertelli AA, Gozzini A, Giovannini L. Plasma and tissue resveratrol concentrations and pharmacological activity. Drugs under experimental and clinical research. 1998; 24(3):133-138. PMID: 9825229.
38. Cottart CH, Nivet-Antoine V, Laguillier-Morizot C, Beaudeux JL. Resveratrol bioavailability and toxicity in humans. Molecular nutrition & food research. 2010; 54(1):7-16.
39. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr., Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug metabolism and disposition: The biological fate of chemicals. 2004; 32(12):1377-1382. PMID: 15333514.